FDA's Tobacco Center To Mull First Modified-Risk Claim Application
This article was originally published in The Tan Sheet
Executive Summary
FDA will have a complex public health impact equation to balance as its Center for Tobacco Products faces its first application for "modified-risk" tobacco product claims
You may also be interested in...
FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
AHA rejects smokeless tobacco for smoking cessation
Smokeless tobacco products are not appropriate alternatives to nicotine-replacement therapies, the American Heart Association says. A policy statement published online Sept. 13 in AHA's journal Circulation notes that, despite the push for smokeless tobacco as a risk-reduction strategy for smokers, the association "does not recommend the use of ST as an alternative to cigarette smoking or as a smoking-cessation product." Smokeless products, such as Phillip Morris' snus, produce plasma nicotine levels in users too low to make them as effective for cessation as NRTs, which "have an impressive safety record," according to the AHA team led by Mariann Piano of the University of Illinois at Chicago's Department of Biobehavioral Health Science. FDA is weighing Star Scientific's citizen petition for "modified-risk" claims for its smokeless tobacco products (1"The Tan Sheet" March 1, 2010)
FDA Looks At Dissolvable Tobacco Products' Impact On Cessation
FDA asks for public comment on the impact of dissolvable tobacco products on public health, specifically asking how use of the products will affect tobacco-use cessation